1631.9000 -2.30 (-0.14%)
NSE Jan 23, 2026 15:31 PM
Volume: 1.7M
 

1631.90
-0.14%
Emkay
Sun’s 2QFY26 EBITDA was ahead of the street and our estimates (by ~12%), on the back of a marginally higher gross margin and lower R&D spend.
Sun Pharmaceutical I.. has an average target of 1921.38 from 8 brokers.
More from Sun Pharmaceutical Industries Ltd.
Recommended